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Abstract
Purpose—An assay for the single nucleotide polymorphism (SNP) rs61764370 has recently been
commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with
family histories of the disease. rs67164370 is in a 3′UTR miRNA binding site of the KRAS
oncogene, and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one
published paper, analyzing fewer than 1,000 subjects in total, has examined this association.
Experimental Design—Risk association was evaluated in 8,669 cases of invasive EOC and
10,012 controls from nineteen studies participating in the Ovarian Cancer Association
Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the
Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in
a subset of five studies with progression-free survival data and eighteen studies with all-cause
mortality data.
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Results—No evidence of association was observed between genotype and risk of unselected
EOC (odds ratio (OR)=1.02, 95% confidence interval (CI)=0.95–1.10), serous EOC (OR=1.08,
95%CI=0.98–1.18), familial EOC (OR=1.09, 95%CI=0.78–1.54), or among women carrying
deleterious mutations in BRCA1 (OR=1.09, 95%CI=0.88–1.36). There was little evidence for
association with survival time among unselected cases (hazard ratio (HR)=1.10, 95%CI=0.99–
1.22), among serous cases (HR=1.12, 95%CI=0.99–1.28), or with progression-free survival in 540
cases treated with carboplatin and paclitaxel (HR=1.18, 95%CI=0.93–1.52).
Conclusions—These data exclude the possibility of an association between rs61764370 and a
clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for
ovarian cancer clinical risk prediction therefore appears unwarranted.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth-most common cancer in women. It generally
presents as advanced disease with poor prognosis. Family and twin studies have suggested
that inherited genetic variation plays an appreciable part in determining individual risk.
However, until recently, knowledge of genetic susceptibility was limited to rare, highly-
penetrant alleles in a handful of genes including BRCA1, BRCA2 and the mismatch repair
genes (1). In the past two years, genome-wide association studies have identified common
susceptibility alleles at four loci at highly stringent levels of statistical significance
(P<10−8), but these alleles have small effects on disease risk (per-allele OR<1.3) and
explain a small fraction of the genetic component of disease risk (2–4). Many candidate
gene studies have identified possible common ovarian cancer susceptibility alleles, but most
are likely to represent false-positive associations as none have been reported at the levels of
statistical significance required when testing hypotheses with low prior probabilities of
association (1).
In July 2010, a single nucleotide polymorphism (SNP), rs61764370, located in the 3′UTR of
the KRAS oncogene, was reported to be associated with risk of unselected epithelial ovarian
cancer (5). The variant was also reported to be associated with a stronger risk in women
carrying BRCA1 mutations, in women not carrying BRCA1 or BRCA2 mutations but with a
family history of the disease, as well as associated with poorer progression-free survival (5).
This SNP was thought to be a strong candidate for cancer risk as it lies in a miRNA binding
site, and associations between miRNA mutations or mis-expression and risk of some human
cancers have been seen. These observations suggested that miRNAs can function as tumor
suppressors or oncogenes (6). An assay to determine genotype at rs61764370 has
subsequently been marketed as a commercial test to determine risk in women with a family
history of ovarian cancer (http://www.miradx.com). However, as with other candidate gene
studies, the reported association was not at a level of statistical significance that is regarded
as definitive for common susceptibility alleles (7), nor was the magnitude of risk sufficient
for this SNP to be acceptable as a useful clinical marker of ovarian cancer risk. The present
work therefore sought to: i) replicate the association in a robust manner in multiple study
populations genotyped to a high standard with stringent quality assurance procedures; ii)
assess the association between genotype at this locus and ovarian cancer risk in women with
family histories or who carry deleterious mutations in BRCA1; and iii) examine the
hypothesis that the SNP is associated with differences in post-diagnosis progression-free
survival or all-cause mortality.
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METHODS
Study populations
Nineteen ovarian cancer case-control sets and one case series participating in the Ovarian
Cancer Association Consortium (OCAC), and one additional case series, contributed data to
the analyses (Table 1). Three of the case-control sets were each comprised of a case series
matched to controls from the same geographical region: PVM, UK2 and UK-GWAS.
Survival time analysis was based on data from eighteen case series including the additional
publicly available data for 359 ovarian cancer cases from The Cancer Genome Atlas
(http://cancergenome.nih.gov/) that had information on all-cause mortality. The analysis of
progression-free survival was based on data from five case series. Finally, data from 683
cases and 2,044 controls enrolled in a stage I project of the Consortium of Investigators of
Modifiers of BRCA1/2 (see reference (8) for details of studies participating in CIMBA) were
used to examine risk among women carrying deleterious BRCA1 mutations. Each study was
approved by a governing research ethics committee and all study subjects provided written
informed consent. Clinical and questionnaire data included tumor behavior, histology, stage
and grade, age at diagnosis (or at comparable date for controls), family history of ovarian
cancer, and ethnicity/race.
Survival-time data were available for cases from eighteen studies (BEL, DOV, UCR, GER,
HOP, LAX, MAY, NCO, PVD, RMH, SEA, SOC, SRO, TBO, TCGA, UCI, UKO, USC)
and clinical information on chemotherapy, residual disease after surgery and time to
progression was collected in five studies (BEL, LAX, MAY, SRO, TCGA). All of the
women included in the analysis of progression-free survival (PFS) had at least four cycles of
carboplatin and paclitaxel as part of primary treatment. PFS was defined as the time interval
between the date of histologic diagnosis and the first confirmed sign of disease recurrence or
progression (9).
Genotyping
Genotyping of thirteen case-control sets was performed in a single laboratory using a 5′
nuclease Taqman allelic discrimination assay (Applied Biosystems, Foster City, CA) as part
of a 96-SNP Fluidigm multiplex (10 studies) or--with the same batch of Taqman reagents--
using the 7900HT Sequence Detection Software (Applied Biosystems) (three studies) (Table
1). Details of OCAC’s quality control (QC) criteria have been described previously (10);
they include genotyping of a common set of 95 DNAs (90 CEPH trios and five duplicate
samples) and comparison to the genotypes for the same samples as reported by HapMap.
However, rs61764370 was not genotyped in the HapMap project. Based on sequence data
for 57 individuals of European origin from the 1000Genomes project
(http://www.1000genomes.org), a HapMap SNP, rs17388148, was found to be strongly
correlated (r2=0.97) with rs61764370. The concordance between the CEPH trio genotype
data for rs61764370 and the HapMap genotypes for rs17388148 was 100%. Therefore, data
on rs17388148 were obtained from three genome-wide association studies (GWAS), where
cases and controls had been genotyped using Illumina genome-wide SNP arrays (1,2,4,8)
(Table 1). Neither rs61764370 nor rs17388148 were included on the Illumina arrays used in
these GWAS studies, but imputed genotypes were available for rs17388148. These
genotypes were provided as the estimated number of rare alleles carried (0 to 2 on a
continuous scale). The accuracy of the imputation as calculated by the program MACH of Li
and Abecasis (11) for the North American studies (BWH, MAY, NCO, TBO and TOR) was
r2=0.977. This high accuracy of the imputation was evidently due to the presence of a
nearby SNP (rs12305513, 17kb away) in high LD (r2=1 in HapMap) with rs17388148.
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Statistical Analyses
Analyses were restricted to white non-Hispanic women based on self-reported ethnic origin
for all of the studies, with the exception of the TCGA, MAY, NCO, TOR, TBO and UK-
GWAS controls. For these studies, genome-wide genotype data were used to estimate
intercontinental ancestry and women of less than 90 percent European ancestry were
excluded (see methods in reference (3) for details). Cases with borderline (low malignant
potential) epithelial ovarian cancer were also excluded, as were 22 cases from TCGA that
had been provided to TCGA as part of the MAY case-control study. Departure of genotype
frequencies from those expected under Hardy-Weinberg equilibrium was assessed using a
chi-square test for each study that was directly genotyped. The association between SNP and
disease risk was evaluated using unconditional logistic regression in which number of copies
of the minor (infrequent) allele was treated as a continuous variable. This provides an
estimate of the per-allele odds ratio (OR) and 95% confidence interval (95% CI). Models
adjusted for age categories (<40, 40–49, 50–59, 60–69 and ≥70 years) were also considered.
Each case-control set was analyzed individually and the pooled result was obtained by
combining the log odds-ratios using standard inverse variance-weighted meta-analytic
methods. Analysis of the BRCA1 mutation carrier cohort was carried out using a time-to-
event analysis framework that models the association between genotype and ovarian cancer
risk as a hazard ratio. Because mutation carriers were not sampled randomly with respect to
their disease status, standard methods of survival analysis may lead to biased estimates of
associations. Therefore, analyses were carried out by modeling the retrospective likelihood
of observed genotype conditional on disease phenotype (see references (8,12) for details).
Associations between genotype and progression-free survival and all-cause mortality were
evaluated using proportional hazards regression. Because the EOC cases were recruited at
variable times after diagnosis, regression analysis of all-cause mortality allowed for left
truncation, with time at risk starting on date of diagnosis and time under observation
beginning at the time of study entry. This method generates an unbiased estimate of the
hazard ratio provided that the proportional hazards assumption is reasonably correct (13).
Cause-specific mortality was not available for most studies, so the analysis of all-cause
mortality was right-censored at five years after diagnosis in order to minimize the proportion
of deaths from causes other than ovarian cancer. The analysis of progression-free survival
was adjusted for stage and residual disease, and survival time ended at time of progression
or was censored at time of last follow-up.
RESULTS
Details of the nineteen case-control sets used in our analyses are given in Table 1. Genotype
data from these sets were available for 8,669 cases and 10,012 controls (Table 2). All studies
passed the OCAC criteria for genotyping quality. Genotype frequencies were close to those
expected under Hardy Weinberg equilibrium in both cases and controls for the thirteen
directly genotyped studies. No evidence was found for association between rs61764370 and
invasive EOC in univariate analysis (OR = 1.02, 95% CI 0.95–1.10, P = 0.44), with minimal
heterogeneity of risk between studies (P = 0.28). Study specific odds ratios are shown in
Figure 1a. When studies with directly genotyped data and with imputed data were analyzed
separately, the overall OR in the genotyped studies was 0.96 (95% CI 0.87–1.06, P = 0.42)
compared to 1.08 (95% CI 0.97–1.20, P = 0.15) in the imputed data studies. Adjusting for
age at diagnosis/interview made little difference to the results (data not shown). No
differences in risk were observed when analyses were restricted to cases who provided blood
samples within 18 months of diagnosis (n = 6,550, OR = 1.02, 95% CI 0.93–1.10, P = 0.72),
cases with serous tumors (Figure 1b, n = 4,706, OR = 1.08, 95% CI 0.98–1.18, P = 0.11), or
cases reporting a family history of ovarian cancer in a first-degree relative (from 6 studies)
(Figure 1c, n = 249, OR = 1.09, 95% CI 0.78–1.54, P = 0.62). Tests for heterogeneity of risk
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between studies in all analyses were not statistically significant. A similar result was seen
for risk of EOC by genotype among 683 cases and 2,044 controls who were carriers of
BRCA1 mutations (HR = 1.09, 95% CI 0.88–1.36, P = 0.40).
Survival-time data were available for 6,002 cases of the 6,826 total from eighteen case
series, including 13,696 person-years at risk and 2,044 deaths. Little evidence of association
was observed between rs61764370 genotype and all-cause mortality within five years of
diagnosis (HR = 1.10, 95% CI 0.99–1.22, P = 0.08), with no evidence of heterogeneity of
the hazard ratio between studies (P = 0.89). Results of analyses restricted to serous subtype
(HR = 1.12, 95% CI 0.99–1.28, P = 0.08) or adjusted for tumor stage and grade (HR = 1.06,
95% CI 0.96–1.18, P = 0.27) were similar. There was also little evidence for association
between genotype and progression-free survival in 540 high-grade serous cases known to
have been treated with carboplatin and paclitaxel (HR = 1.18, 95% CI 0.93–1.52, P = 0.16).
DISCUSSION
This study provides no evidence to support the previously reported associations between
rs61764370 and risk of epithelial ovarian cancer. The relative risk given by Ratner and
colleagues for their replication data set of unselected cases was 1.70 (95% CI 1.11–2.63, P =
0.016) (5). The confidence intervals in the present study do not overlap with these. The
power of the present study to detect an allele conferring a relative risk of 1.3 under either a
dominant or log-additive genetic model with a Type 1 error rate of 10−4 was greater than
99%, strongly suggesting that the association observed by Ratner and colleagues was a
chance finding or possibly due to subtle genotyping errors. This observation is not
surprising. Associations with modest P-values that are declared as positive are very likely to
be false positives when the prior probability of association is low (14). In genetic association
studies, even if evidence exists that a variant has functional effects, the prior probability of
association at a relative risk of 1.5 is unlikely to be more than 1:100, and given that only a
handful of loci conferring relative risks of more than 1.5 have been found for any cancer, the
prior probability is likely to be much less. Based on the methodology of Wacholder and
colleagues (14), assuming a prior of 1:100, the probability that the association reported by
Ratner and colleagues was a false positive is 86 percent. Under more likely, smaller prior
probabilities the false positive probability will approach 100 percent. For familial ovarian
cancer, the power of the present study to detect a relative risk of 2.0 was over 95% at a type
1 error rate of 0.05, again suggesting it is unlikely that the present analyses have missed a
true association of this magnitude with familial ovarian cancer.
Statistical power to detect an allele with weaker effects is more limited. For example, if the
true relative risk were 1.15 under a co-dominant genetic model--similar to the relative risk
conferred by an allele with the biggest risk detected in a recent well-powered lung-cancer
GWAS (15)--power at a type 1 error rate of 0.001 would be reduced to 70%. A very modest
association between the rs61764370 variant and a slightly increased risk of ovarian cancer
cannot therefore be excluded. Neither has the present study shown much evidence for
association between genotype at this locus and other related phenotypes: EOC risk in
carriers of deleterious BRCA1 mutations or in women with family histories of EOC, all-
cause mortality after diagnosis of EOC, and progression-free survival in EOC cases treated
with carboplatin and paclitaxel.
In summary, the possibility that the minor (infrequent) allele of rs61764340 is associated
with an appreciable risk of epithelial ovarian cancer is excluded. Furthermore, it is debatable
whether a single risk allele, even one conferring a relative risk as high as 2.0, has clinical
utility, particularly in a disease with lifetime risk as low as it is in invasive epithelial ovarian
cancer (1 in 70), and even among women with a family history of the disease (16). The
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marketing of a commercial assay for rs61764370 for clinical use among unselected cases, or
women with family histories of ovarian cancer or who are carriers of BRCA1 mutations, in
the absence of convincing evidence for association, is not warranted.
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Figure 1.
Funnel plots of study-specific odds ratios for association between rs61764370 and ovarian
cancer risk. (a) all cases; (b) serous cases; (c) cases with a family history of ovarian cancer
in a first-degree relative.
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